Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC.

被引：0

作者：

Jacobs, Ryan ^{[1
]}

Fong, Jason ^{[1
]}

Moravec, David ^{[1
]}

Botting, Greg ^{[1
]}

Bomgarden, Ryan ^{[2
]}

Rogers, John ^{[2
]}

Viner, Rosa ^{[3
]}

Blank, Michael ^{[3
]}

Puri, Neelu ^{[1
]}

机构：

[1] Univ Illinois, Rockford, IL USA

[2] Thermo Fisher Sci, Rockford, IL USA

[3] Thermo Fisher Sci, San Jose, CA USA

来源：

CANCER RESEARCH | 2013年 / 73卷 / 08期

关键词：

D O I：

10.1158/1538-7445.AM2013-5653

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5653

引用

页数：1

共 50 条

[31] KRAS mutation in the primary or acquired resistance of Chinese NSCLC to EGFR tyrosine kinase inhibitors
Chen, H.
Wu, Y.
Zhang, X.
Chen, Z.
Guo, A.
Cheng, H.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[32] Usefulness of peripheral blood for monitoring of acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC
Kobayashi, Naomi
Sueoka-Aragane, Naoko
Umeguchi, Hitomi
Nakamura, Tomomi
Sato, Akemi
Komiya, Kazutoshi
Takeda, Yuji
Hayashi, Shinichiro
Sueoka, Eisaburo
Kimura, Shinya
CANCER RESEARCH, 2014, 74 (19)
[33] The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach
Allen, Joanne V.
Bardelle, Catherine
Blades, Kevin
Buttar, Dave
Chapman, Louise
Colclough, Nicola
Dossetter, Alexander G.
Garner, Andrew P.
Girdwood, Alan
Lambert, Christine
Leach, Andrew G.
Law, Brian
Major, John
Plant, Helen
Slater, Anthony M.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (18) : 5224 - 5229
[34] Identification of Inhibitors of the Tyrosine Kinase c-Met by Structure-Based Virtual Screening
Lemcke, Thomas
Dreher, Jan
Rarey, Matthias
Totzke, Frank
Schaechtele, Christoph
Kubbutat, Michael H. G.
Kunick, Conrad
MOLECULAR INFORMATICS, 2011, 30 (2-3) : 145 - 150
[35] Molecular imaging of c-Met tyrosine kinase activity
Zhang, Limin
Virani, Shama
Zhang, Yu
Bhojani, Mahaveer S.
Burgess, Teresa L.
Coxon, Angela
Galban, Craig J.
Ross, Brian D.
Rehemtulla, Alnawaz
ANALYTICAL BIOCHEMISTRY, 2011, 412 (01) : 1 - 8
[36] Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Lihua Huang
Liwu Fu
Acta Pharmaceutica Sinica B, 2015, 5 (05) : 390 - 401
[37] Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Huang, Lihua
Fu, Liwu
ACTA PHARMACEUTICA SINICA B, 2015, 5 (05) : 390 - 401
[38] Management of Resistance to EGFR Tyrosine Kinase Inhibitors
Mitsudomi, Tetsuya
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S82 - S83
[39] Development of new c-Met inhibitors and application of corresponding multitarget tyrosine kinase inhibitors in tumor therapy
Zeng, Xiangcong
Hu, Yuanwen
Xu, Zhi
Wu, Xiaoyu
Xiong, Yun
Liu, Shengpeng
SOFT COMPUTING, 2023,
[40] A new generation of EGFR tyrosine-kinase inhibitors in NSCLC
Hirsch, Fred R.
Bunn, Paul A., Jr.
LANCET ONCOLOGY, 2012, 13 (05): : 442 - 443

← 1 2 3 4 5 →